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Abstract
Cardiovascular disease poses a major challenge for the 21st century. Although 
good control of blood pressure and type 2 diabetes and reducing low-density 
lipoprotein-cholesterol levels can improve cardiovascular outcomes, a substan-
tial residual risk remains existed after treatment in most patient populations. 
Recently, many efforts have been directed at finding the important role of low 
high-density-lipoprotein cholesterol, high triglycerides, especially triglyceride-
rich lipoproteins and lipoprotein (a) in the metabolism of atherosclerotic plaque 
formation Therefore, based on the recent evidence, identification and treatment 
of these risk factors may play a role in optimizing therapeutic strategy, particu-
larly in high risk subjects along with conventional treatment. In clinical practice, 
adequate attention should be paid when screening and managing residual car-
diovascular risk factors in dyslipidemia in term of individualized approach. The 
ongoing trials will give more answers to elucidate this important area.
Keywords: cardiovascular disease, dyslipidemia, residual risk factors, 
hypertriglyceridemia, low HDL-C, lipoprotein (a)
1. Introduction
Risk factors for cardiovascular disease (CVD) are specific lifestyles, behaviors 
and a set of conditions that increase likelihood of CVD. An individual may have 
more than one cardiovascular (CV) risk factors. In fact, CV risk factors often 
appear coherently. The more risk factors, the greater the risk of CVD. However, the 
individual with increased risk does not necessarily develop cardiovascular diseases.
A number of factors have been linked to an increased risk of cardiovascular dis-
ease which can be classified as (1) Unmodifiable risk factors: age (men over 45 years 
old, women over 55 years old), gender and family history of early CVD (men under 
55 years old, women under 65 years old) and (2) Modifiable risk factors: unhealthy 
diets, high blood pressure, dyslipidemia, smoking, overweight, obesity, pre-diabetes 
or diabetes, sedentary lifestyle [1–3].
In addition, extended CV risk factors were proposed, including: metabolic syn-
drome (insulin resistance syndrome, syndrome X) including triglyceridemia, chronic 
kidney disease (CKD) with reduced glomerular filtration rate [15–59 ml/min/1.73 m2], 
chronic inflammatory conditions (rheumatic disease, HIV), early menopause 
(< 40 years), history of eclampsia, high-risk ethnicity (South Asian), elevated 
lipoprotein (a) [Lp(a)] ≥ 50 mg/dL (≥ 125 nmol/L) or elevated apolipoprotein B 
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(ApoB) ≥ 130 mg/dL, C-reactive protein (CRP) ≥ 2 mg/L and ankle-brachial  
index <0.9 [4].
Residual CV risk factor is defined as the risk of CV events that persists despite 
achieving treatment goals for low-density lipoprotein cholesterol (LDL-C), blood 
pressure and blood glucose as recommended by current evidence-based guide-
lines [5, 6]. Residual CV risk factors include LDL-C > 100 mg/dL, high-sensitive 
C-reactive protein (hsCRP) > 2 mg/l, triglyceride (TG) > 200 mg/dL, high-density 
lipoprotein cholesterol (HDL-C) < 40 mg/dL, Lp(a) > 50 mg/dL [7]. The origin 
of residual CV risk factors in dyslipidemia is based on atherogenic dyslipidemia 
characterized by elevated TG and triglyceride-rich lipoproteins (TRLs), decreased 
HDL-C, and qualitative changes of lipoprotein particles [8–10].
2. Epidemiology
Most large studies extending over the last 25 years suggested that the leading 
cause of atheroslerotic cardiovascular disease (ASCVD) is high LDL-C levels and 
this has been widely recognized and accepted [9, 11]. Furthermore, there is also 
growing evidence that increased levels of LDL-C and other ApoB containers, 
including very low density lipoprotein cholesterol (VLDL-C), intermediate density 
lipoprotein cholesterol (IDL-C) and Lp(a), are directly related to the progression of 
ASCVD [12, 13]. In 2010, a multicenter study analyzing data from 26 randomized 
clinical trials in 2009 demonstrated that statins are effective in lowering LDL-C 
blood levels and controlling blood glucose levels. LDL-C at the recommended level 
is beneficial in reducing atherosclerotic CV events and CV mortality [14].
However, studies in recent years have revealed that control of plasma LDL-C con-
centrations is not the only goal of reducing the risk of CVD [15]. Based on the results of 
their study, Cannon et al. demonstrated an ongoing risk of major CV events after treat-
ment with high doses of atorvastatin or pravastatin. The data signified that up to 26.3% 
in the atorvastatin-treated group and 22.4% in the pravastatin-treated group experi-
enced a major CV event or death [16]. This evidence suggests that the goal of reducing 
the risk of CVD requires control not only of blood LDL-C levels but also of residual CV 
risk factors in other dyslipidemia, including TG and TRLs, HDL-C and Lp(a) [9].
3. Residual risk factors in dyslipidemia
3.1 Pathogenesis of atherosclerosis
Atherosclerosis is a complex phenomenon that is involved by a number of 
factors. Firstly, when the vascular endothelial cell layer is injured, the synthesis 
of nitrite oxide (NO), a chemical that protects blood vessels, is reduced, while the 
production of oxidants rises [17, 18]. Infiltration of ApoBs including remnants of 
chylomicron, VLDL-C, IDL-C, LDL-C and Lp(a) into the endothelial layer. The 
ApoBs that are retained in the vessel wall oxidize, triggering a cascade of biological 
events that result in an inflammatory response [19, 20]. Furthermore, platelets are 
stimulated to cause chronic vascular inflammation which leads to leukocyte recruit-
ment [21, 22]. Monocytes and neutrophils penetrate the endothelial layer into the 
arterial wall. Macrophages that have been differentiated from monocytes amplify 
lipid absorption and produce foam cells, which play a key role in the formation and 
instability of atherosclerotic plaques. T lymphocytes, mastocytes, and other inflam-
matory cells penetrate the lesion and help to continue the noxious inflammatory 
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response [20–24]. This process is also maintained and enhanced through signaling 
pathways such as MCP-1, M-CFS, GM-CFS [25–27]. As a result, the plaque ruptures 
and leads to clinical manifestations for example, myocardial infarction or stroke.
3.2 Hypertriglyceridemia and related markers
The function of TG in the etiology of atherosclerosis has garnered limited atten-
tion in recent years, with most studies focusing on the benefits of raising HDL-C. 
Contemporary clinical and genetic evidence, on the other hand, suggests that TG, 
especially TRLs, and apoprotein C3, play essential roles in the etiology of athero-
sclerosis. Therefore, TG and TRLs are getting increasing attention and are becom-
ing one of the therapeutic targets for lowering the risk of ASCVD [29].
TG is the main component in the structure of the TRL group including VLDL-C 
and chylomicrons which are synthesized in the liver and small intestine, respec-
tively [28, 30]. The metabolism of TG and TRLs has the involvement of lipoprotein 
lipase (LPL) which is capable of activating the hydrolysis of the TG component in 
the core of TRLs into fatty acids. As a result, residual VLDL-C and residual chylo-
microns are formed, which contain less TG and more cholesterol than normal TRLs 
[28, 31]. A portion of VLDL-C residues and residual chylomicrons are captured in 
the liver and neutralized by hepatic bile. The remainder is metabolized again by LPL 
or hepatic lipase enzymes, forming cholesterol-rich LDL-C [28, 30]. The residual 
LDL-C, VLDL-C, and residual chylomicrons are all cholesterol-rich lipoproteins 
and are classified as non-HDL [28, 32]. As with LDL-C, residual VLDL-C and chy-
plomicron molecules can be engulfed by macrophages in the vascular wall, which 
contributes to vascular inflammation and progression of atheromal. However, 
unlike LDL-C, the residual VLDL-C and chylomicron molecules do not require 
oxidation when participating in the process of atherosclerosis [28, 30]. Many factors 
impact the metabolism of TG and TRLs, with LPL playing a major role. The activ-
ity of the LPL enzyme has a direct effect on the concentration of TG and TRLs in 
the blood; for example, increasing LPL activity lowers TG and TRL concentrations 
while increasing VLDL-C molecules and residual chylomicrons, and vice versa 
(Figure 1).
The reduction in TG and TRLs metabolism leads to less cholesterol-rich lipopro-
tein concentrations and is expected to reduce the risk of atherosclerosis. However, 
intensive genetic and molecular biology studies of TG, TRLs and LPL all showed 
conflicting results. The first observational studies in the field of genetics related to 
TG, TRLs and LPL found that mutations that decrease TRLs metabolism were asso-
ciated with atherosclerosis and coronary artery disease, whereas mutations TRLs 
metabolism enhancer had the opposite effect. Several mutations directly in the 
LPL enzyme associated with CVD risk have been observed including Gly188Glu, 
Asp91Asn and Asn291Ser substitution mutations. In which, the Gly188Glu sub-
stitution mutation in LPL can increase the risk of coronary heart disease 5 times 
higher than those without the mutation [33]. ApoC-II and ApoA-V loss-of-function 
mutations, both have been conveyed to increase blood TG, increase the risk of 
myocardial infarction and coronary artery disease, while mutations in the APOC3 
gene - the gene that codes for Apo C-III - such as the RX 9 mutation and some other 
rare mutations give the opposite result [28, 34]. Most recently, ANGPTL4 mutations 
have appeared to reduce TG levels and reduced the risk of coronary artery disease. 
When conducting whole-chromosome studies on single-nucleotide polymorphisms 
(SNPs), susceptibility loci in the genomic regions encoding ApoC-III, ApoA-V, 
ANGPTL3, and ANGPTL4 were revealed to be associated with ASCVD, which 
lays the foundation for gene therapy to improve CV risk. In addition, there are 
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many other genetic studies with similar results regarding the role of TG in vascular 
events [28].
Due to the inverse correlation of HDL-C and TG, most of the previous epide-
miological studies intimated the association between increased TG and atheroscle-
rosis, which was explained by the lowering effect of HDL-C. However, there are 
studies that refute this view and provide strong evidence that TG is an independent 
factor affecting the risk of CV events. Furthermore, there appears to be a positive 
correlation between serum TG levels and mortality risk, even when adjusted for 
HDL-C and other factors [28].
With a few other CVD not caused by atherosclerosis, TG also showed a similar 
association. One study found that increase levels of TG and residual cholesterol 
molecules (total cholesterol minus LDL-C and HDL-C) were risks of aortic 
stenosis [35].
Treatment of hypertriglyceridemia
Because of the harmful effects of TG on the cardiovascular system, strategies to 
control TG levels were rapidly investigated to contribute to the control of CV risk in 
general population. Several epidemiological studies have indicated a reduction in the 
risk of CV events in subjects regularly consuming fish or foods rich in omega-3 fatty 
acid (EPA), which has been proved to reduce TG level [36–38]. However, studies 
testing natural EPA in subjects with ASCVD or heart failure or at high CV risk such 
as the ORIGIN study and most recently the STRENGTH study have showed no 
beneficial effect [39, 40]. Similarly, most trials of TG-lowering therapies have failed 
to improve CV risk. Until 2019, the REDUCE IT trial – a multicenter, double-blind, 
randomized, placebo-controlled study – was performed in statin-treated diabetic 
patients with CVD or other CV risk factors having TG levels between 135 and 
499 mg/dl (1.52 to 5.63 mmol/L) and blood LDL-C levels between 41 and 100 mg/dl 
(1.06 to 2.59). mmol/L). There were one group treated with icosapent ethyl - a syn-
thetic derivative of EPA with TG-lowering effects - and a placebo group. The results 
Figure 1. 
The center role of LDL-C and TRLs in the formation of atherosclerotic plaque. ANGPTL = angiopoietin like 
protein, HL = hepatic lipase, LPL = lipoprotein lipase.
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concluded that in patients with elevated TG, the use of icosapent ethyl reduced 
significantly CV events [41]. In addition to TG-reducing effect, the CV benefits of 
icosapent ethyl are also attributed to its effects on the main mechanisms underlying 
the progression of atherosclerosis, such as reduced inflammation and anti-oxidation, 
which stabilize and even regress atherosclerotic plaques [42]. Up to now, icosapent 
ethyl is considered a potential drug to help eliminate the residual CV risk caused by 
hypertriglyceridemia (Figure 2).
Research on the effects of fibrates which is a potent TG-lowering agent on 
CVD was also conducted quite early. In 1975, clofibrate in combination with 
niacin showed no significant benefit in reducing the risk of CVD [43]. However, 
VA-HIT study compared the gemfibrozil-treated group with the placebo group 
in patients with blood HDL-C levels <40 mg/dL and blood LDL-C levels 
<140 mg/dL showed effects on lipid parameters: HDL-C levels increased by 6%, 
total cholesterol decreased by 4% and TG decreased by 31% compared to the 
placebo group. In addition, VA-HIT also uncovered that gemfibrozil reduced the 
risk of mortality from major vascular events such as coronary artery disease, 
myocardial infarction, and stroke by 24% [44]. However, in 2010, ACCORD 
trial on combination of fenofibrate and statin in type 2 diabetes showed no 
favorable results [45]. A multicenter meta-analysis examinining data from 18 
studies of fibrates during 1950–2010 to further assess their impact on CVD 
revealed fibrates decreased the risk of major CV events by 10% and coronary 
events by 13% but did not lower the overall risk of stroke or mortality rate [46]. 
With these results, there is practically no clear evidence that fibrates are benefi-
cial in improving the risk of CVD or vascular events.
Novel therapies of hypertriglyceridemia are being applied to achieve maximum 
efficacy while minimizing undesirable side effects. For example, AKCEA-APOCIII-
LRx is targeted on inhibiting the synthesis of Apo C-III by hindering the mRNA 
that translates it. In healthy volunteers, clinical trials of the treatment revealed a 
reduction in the risk of CV events in the treated group, as well as acceptable toler-
ability [47].
Residual lipoprotein cholesterol (RLP-C) which has close relation with TG level 
has also recently been demonstrated to be a residual CV risk factor even in those 
Figure 2. 
(A) The Kaplan–Meier event curves for the primary end point of CV events without death. There was a 
statistically significant difference in primary CV events in the icosapent ethyl group (17.2%) compared with 
the placebo group (22%), corresponding to an absolute between-group difference of 4.8 percentage points, 
hazard ratio, 0.75 (95% CI, 0.68–0.83) P < 0.001, NNT = 21 over a median follow-up of 4.9 years. (B) The 
Kaplan–Meier event curves for the secondary end point of CV events without death. There was a statistically 
significant difference in secondary CV events in the icosapent ethyl group (17.2%) compared with the placebo 
group (22%), corresponding to an absolute between-group difference of 3.6 percentage points, hazard ratio, 
0.74 (95% CI, 0.65–0.83) P < 0.001, NNT = 28 over a median follow-up of 4.9 years. NNT = number needed to 
treat, Cl = confidence interval. Reproduced with permission from Deepak L. Bhatt, M.D., 2019 [41].
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with good LDL-C control. Elevated blood levels of RLP-C have been proved to 
predict coronary and other CV events [35, 48]. This is a new direction that need 
investigating in order to enhance the accuracy of assessing residual CV risk. In addi-
tion, more RLP-C intervention trials are required to demonstate the effect in CVD 
prophylaxis.
3.3 Low HDL-C
Research on the role of TG and TRLs in atherosclerotic disease are progres-
sively providing conclusive evidence while trials to raise blood HDL-C levels have 
so far failed to show significant clinical benefit. This augments the possibility 
that the previously established causal link between higher HDL-C and a lower 
risk of vascular events is attributable to a comparable reduction in TG as HDL-C 
rises. The function of HDL-C in atherosclerosis-related CVD is still debatable 
nowadays.
There are several factors that contribute to HDL-C to protect blood vessels from 
atherosclerosis. The HDL-C molecule is responsible for cholesterol transfer from 
organs and peripheral blood vessels to the liver for biliary elimination. HDL-C 
also diminishes immune cell adherence and increases vasodilating process as well 
as inhibits platelet aggregation via prostacyclin. Prostacyclin modulation, in turn, 
aids in the breakdown of fibrin and thrombolysis in couple with decreasing inflam-
matory mediators and restoring vascular endothelial cell function. In addition, 
HDL-C is an inherent antioxidant involved in the preservation of blood vessels from 
oxidative damage [8, 49].
It is evident that HDL-C can prevent blood vessels from atherosclerosis. 
However, the role of HDL-C in lowering the overall risk of cardiovascular disease 
remains unknown. While epidemiological studies linked HDL-C to a lower risk 
of atherosclerotic CV events [50, 51], genetic study found that HDL-C had no 
effect on CV event risk [52, 53]. Indeed, when delving into a few gene mutations 
related to Scavenger receptor class B type 1 (SR-BI) and Cholesteryl ester transfer 
protein (CEPT) receptors - two components involved in HDL-C metabolism, 
these ones affect CV events differently. The pathway of HDL-C metabolism in the 
human body has the participation of SR-BI and CEPT receptors. When these two 
factors lose their function, the concentration of HDL-C in the blood will increase 
[54–56]. Studies in individuals with anomalies in the gene that cause loss of SR-BI 
receptor function have showed an increase in HDL-C levels but also an increased 
risk of CV events [55]. Nevertheless, studies of mutations that reduce function of 
CEPT showed irrelevant outcome. With the Ile405Val substitution alteration on 
CEPT, it is concluded that there was a decrease in CEPT activity and an increase in 
HDL-C regarding gender, but further an increased risk of ischemic heart disease 
in women but not in men [56]. Despite that, studies with other gene mutations 
such as TaqIB, I405V and -629C > A have clarified a reduced risk of coronary 
heart disease [57]. In 2009, a genetic study in different loci of the gene coding for 
CEPT, gave an explaination for this heterogeneity. There was an inverse association 
between HDL-C and the risk of cardiovascular events as a result of mutations; 
however, there are other alterations that do not demonstrate this correlation [8]. 
With achievements in functional decoding of HDL-C in terms of genes, researchers 
and clinical practitioners would assume the role of HDL-C in ASCVD will soon be 
clarified and become a state-of-art implement to assist in the treatment, prognosis, 
and prevention of CVD.
Since the role of HDL-C is uncertain, the use of the HDL-C measurement in 
clinical practice has been limited up until present. Due to the extreme prior belief 
that HDL-C is a favorable factor for lowering CVD risk, HDL-C was added to 
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SCORE – the CV risk assessment model – to create SCORE – HDL-C in European 
Society of Cardiology recommendations for the treatment of dyslipidemia [58, 59]. 
A study published in 2015 evaluated the predictive capacity of two models, SCORE -  
HDL-C and SCORE, and found that while the SCORE - HDL-C did not enhance CV 
mortality prognosis, it did lower the sensitivity of finding persons at high risk of 
CVD in the population [60].
Treatment of low HDL-C
Niacin is a medication that raises HDL-C levels and has been examined  
extensively in clinical studies. Its efficacy in controlling dyslipidemia and 
lowering the risk of cardiovascular disease is not well established. In a 1975 study 
comparing the CV merits of niacin, clofibrate, and placebo, treatment with a 
high dose of 3000 mg/day of moderate-release niacin resulted in a 14% reduc-
tion in coronary mortality, and 26% of stroke death [43]. When the research was 
expanded to include additional possible medicines in the treatment of dyslip-
idemia, such as estrogens, clofibrate, dextrothyroxine sodium, and niacin, and 
compared to lactose as a placebo, niacin was found to be encouraging reducing 
mortality [66]. However, in the AIM-HIGH and HPS2-THRIVE studies, the 
effects of niacin were only significant on lipid parameters without effect on CV 
outcomes [61, 62].
CEPT inhibitors came later than niacin and fibrates in terms of development 
and application. ILLUMINATE, dal-OUTCOMES, ACCELERATE, and REVIEW 
are among the most notable CEPT inhibitor trials to date. Nonetheless, the results 
of this medication were similarly unsuccessful due to inconsistencies in genetic 
research of CEPT. With the exception of the 2017 anacetrapid REVIEW study, 
which described a reduction in coronary events [63], the majority of the remaining 
studies suggested that CEPT inhibitors did not improve CVD risk but increased 
rates of CV mortality or adverse events such as increased CRP levels or increased 
systolic blood pressure [64–66]. Thus, clinical application studies of drugs that 
increase HDL-C have not yet provided evidence that HDL-C is beneficial in CVD.
In addition to the genetic aspect mentioned above, another hypothesis about 
HDL-C levels has been expanded to explicate the incompatible results of studies on 
HDL-C. When examining at HDL-C levels and mortality in the study population, 
several studies found a U-shaped relationship between HDL-C levels and overall mor-
tality rates. This is understandable since extremely low or high HDL-C levels increase 
population mortality [67–69]. In fact, prior HDL-C studies neglected this aspect, 
requiring more study to more correctly assess HDL- C involvement in ASCVD.
Based on the available evidence, it can be stated that HDL-C modification in clinical 
practice is currently restricted. Not all HDL-C-increasing medications yield the same 
outcomes. To better understand the significance of HDL-C, these items must be consid-
ered to a greater extent: the threshold concentration of plasma HDL-C and the genetic 
aspect. It is indeed questionable if increasing HDL-C can assist reducing CV risk.
3.4 Lipoprotein (a)
Lp(a) is made up of an LDL-C molecule covalently bound to an apolipoprotein 
(a) that is homologous to the coagulation factor plasminogen. It also includes an 
apolipoprotein B100 as it contains LDL-C. Therefore, Lp(a) has both atherogenic 
and thrombolytic properties [70, 71]. The ability of Lp(a) to permeate the artery 
wall has been demonstrated [72]. Lp(a) has been showed to increase thrombus 
development, inflammatory response, and foam cell production in both laboratory 
and animal investigations [73].
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Many studies prove that Lp(a) is a factor affecting the morbidity and mortality 
of CVD [74, 75]. The INTERHEART study proclaimed that Lp(a) levels >50 mg/dL 
increased the risk of myocardial ischemia [76]. The effect of Lp(a) on CV risk was 
independent of other risk factors, including LDL-C levels [77, 78]. Thus, elevation 
of blood Lp(a) levels confers a residual CV risk in dyslipidemia, which is similar to 
the role of TG mentioned above. A large study of LPA genetic variants also showed 
an independent role for Lp(a) in relation to coronary events, despite low LDL-C lev-
els with statin therapy [79]. To specify the role of Lp(a) in reducing the risk of CVD, 
a study compared blood levels of Lp(a) with the risk of CVD and LDL-C levels with 
CVD risk, the results showed that the clinical benefit of lowering Lp(a) was directly 
proportional to the reduction of Lp(a) levels. Specifically, a 101.5 mg/dL reduc-
tion in Lp(a) resulted in a clinically significant reduction in CVD risk similar to a 
38.67 mg/dL reduction in LDL-C [80].
Among the factors affecting Lp(a) levels, PCSK9 is one that has been observed 
in clinical trials to reduce Lp(a) concentration [78]. The role of proprotein 
convertase subtilisin/kexin type 9 (PCSK9) in influencing Lp(a) levels was also 
confirmed in a survey of PCSK9 functional-affecting mutants, which explicated 
that overexpressed function mutations of PCSK9 increased the CV risk while 
the PCSK9 R46L mutation reduced its function, showing a reduced risk of aortic 
stenosis and myocardial infarction [81]. The reduction in CV risk is proportional 
to the level of Lp(a) in the blood as mentioned above. Therefore, PCSK9 inhibi-
tors are a potential agent for reducing the incidence of vascular events through its 
effect on Lp(a).
Treatment of high lipoprotein (a)
The cornerstone of current potential drug development is the new evidence on 
the benefits of Lp(a) reduction on the risk of CV events and mortality. Only in the 
last three years have trials of drugs that reduce Lp(a), such as alirocumab and evo-
locumab, been conducted. ODYSSEY OUTCOMES was a large trial of alirocumab, 
the results of which showed that alirocumab reduced the total number of CV events 
and CV mortality in patients diagnosed with acute coronary syndrome (ACS) 
[81]. In 2020, the data from the ODYSSEY OUTCOMES trial were reanalyzed to 
determine the effect of baseline Lp(a) levels and the trend of alirocumab-induced 
change on Lp(a) and LDL-C, results showed that each 5 mg/dL reduction in Lp(a) 
was predictive of a 2.5% reduction in CV events. Therefore, Lp(a) should now be 
considered a therapeutic target, especially after ACS [82]. There was a tremendous 
advantage when comparing alirocumab or evolocumab with placebo or ezetimibe 
plus a statin in another trial; however, the benefit difference between the two 
groups was not significant when comparing the two groups utilizing the combina-
tion of ezetimibe and statin [83].
Currently, new therapies that selectively target Lp(a) are being developed. The 
APO(a)-LRx study is currently ongoing, but preliminary findings indicate that 
APO(a)-LRx has the potential to reduce Lp(a) levels and their effects by up to 80%, 
potentially lowering CV risk [84]. In addition, testing a monoclonal antibody that 
reduces blood Lp(a) levels has demonstrated promising in vitro data [85]. The 
results of these trials are eagerly awaited.
To date, more persuasive evidence has exhibited that TG and Lp(a) are indepen-
dent CV risk factors, even with LDL-C, and should be considered as new thera-
peutic targets in the management of CVD. Meanwhile, the importance of HDL-C 
has decreased compared to the previous era. However, in-depth studies analyzing 
genes and blood HDL-C levels are two hypotheses that need to be further studied to 
clarify the role of HDL-C.
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4.  Situations for considering residual cardiovascular risk factor 
intervention
4.1 After achieving LDL-C target
Based on the close association between hypercholesterolemia, especially 
LDL-C, with the incidence and mortality of ASCVD, the current treatment 
guidelines mainly focus on on lowering LDL-C levels [9, 11]. However, numerous 
clinical trials of statins, non-statin LDL-C lowering agents, and combination 
therapy have shown that the risk of ASCVD persists despite positive LDL-C 
reduction [14, 86, 87]. Accumulating evidence from epidemiological and genetic 
studies, as well as randomized clinical trials, suggests that TRLs [28, 41, 88], 
Lp(a) [77, 79, 82], inflammatory phenomenon [89–91] and thrombosis risk 
[92–95] are associated with risk of ASCVD in individuals with active LDL-C 
control and interventions to these factors yield promising results promise in 
improving the incidence of CV events [96].
Non-HDL-C dyslipidemia plays an important role in the residual risk of CVD. 
Recent recommendations for the quantification of atherogenic lipoproteins in addi-
tion to LDL-C for lipid-lowering strategies have been published [97].
4.2 Post-acute coronary syndrome
Advances in the treatment of ACS over the past few decades have improved 
the clinical outcomes of CV patients [98, 99]. Despite this, a substantial propor-
tion of individuals continue to experience CV events, even when they are actively 
treated according to current guidelines [100]. This residual risk may be due to 
inflammation [90, 101, 102], thrombotic risk [93, 103] and metabolic causes such 
as TG [88, 104], Lp(a) [82, 105] and with or without HDL-C but has not been 
effectively addressed by current recommended approaches and is influenced by 
comorbidities [76, 102].
TG, Lp(a) have been shown to be independent risk factors affecting the risk of 
major CV events, some studies in subjects with a history of ACS also showed a similar 
correlation. Furthermore, the data to date suggest that TG and Lp(a) levels are 
positively correlated with the risk of ASCVD. Therefore, these two factors should be 
considered as new therapeutic targets to reduce residual CV risk [82, 88, 104, 105].
4.3 Diabetes mellitus
Insulin resistance and type 2 diabetes mellitus are associated with increased pro-
duction of TRLs, such as VLDL-C and chylomicrons, as well as smaller and denser 
LDL-C particles (sdLDL-C), which makes LDL-C particles more compressed and 
therefore more prone to induce atherosclerosis. ApoB-100, the primary lipoproteins 
in VLDL-C, IDL-C, and sdLDL-C, as well as ApoB-48, the major lipoproteins in 
chylomicrons, have a significant risk of causing atherosclerosis. Despite effective 
LDL-C control with statin treatment, severe vascular events such as myocardial 
infarction, stroke, stable angina, and other vascular events, along with mortality 
from CV causes, occur substantially more frequently in diabetic patients. This has 
been shown to be related to TG [88, 104] because hyperglycemia is prevalent in 
those with type 2 diabetes mellitus [106]. Therefore, elevated TG is an important 
residual CV risk factor that should be considered in the treatment of diabetes.
In recent years, LDL-C-lowering treatments and other risk factor control strate-
gies have significantly reduced the incidence of CVD, but in patients with type 2 
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to date, it is suggested that non-LDL-C is a necessary therapeutic target in the pre-
vention of CV events, especially in the TRLs group, in the setting of type 2 diabetes 
[107]. Furthermore, numerous studies suggest that low HDL-C levels and high 
TG, particularly TRLs, predict the risk of ASCVD in diabetes 2 which explains how 
low HDL-C levels impact cholesterol conversion from intravascular atherosclerotic 
plaque via CETP in TG metabolism. The consequence of all lipid abnormalities in 
type 2 diabetes is an increased risk of ASCVD. There is strong evidence, both genetic 
and clinical, that reducing residual TRLs and TG is likely to reduce the risk of CVD 
in CKD. diabetic patients with 2-insulin resistance [88, 104, 107]. Interventions on 
ApoC3, ANGPTL3, and ANGTL4 factors are being examined as potential TG- and 
TRL-lowering treatments and risk reductions in CVD, according to preclinical and 
human genetic research.
5. Conclusion
Based on the current evidence, the importance of residual CV risk factors in 
dyslipidemia are undoubtfully obvious. Since the complexity of the pathogenesis 
of atherosclerosis related to dyslipidemia, the recent interventional studies have 
shown controversial results. Therefore, identification and treatment of these risk 
factors is critical to optimizing treatment, particularly in subjects with recurrent 
vascular events, despite optimal treatment of traditional CV risk factors. In clinical 
practice, adequate attention should be paid when screening and managing residual 
CV risk factors in dyslipidemia in individualized approach. The ongoing trials will 
give more answers to elucidate this important clinical area.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
11
Residual Cardiovascular Risk Factors in Dyslipidemia
DOI: http://dx.doi.org/10.5772/intechopen.100046
References
[1] D. K. Arnett et al., 2019 ACC/AHA 
Guideline on the Primary Prevention of 
Cardiovascular Disease: A Report of the 
American College of Cardiology/
American Heart Association Task Force 
on Clinical Practice Guidelines, vol. 140, 
no. 11. 2019.
[2] “Heart-Healthy Living | NHLBI, 
NIH.” https://www.nhlbi.nih.gov/
health-topics/heart-healthy-living 
(accessed Jun. 26, 2021).
[3] H. Kesteloot, “Prevention of 
cardiovascular disease,” Tijdschr. 
Geneeskd., vol. 34, no. 10, pp. 627-630, 
1978, doi: 10.1016/s0749-0690 
(02)00015-0.
[4] S. M. Grundy et al., “WRITING 
COMMITTEE MEMBERS 




Guideline on the Management of Blood 
Cholesterol Circulation,” Circulation, 
vol. 139, pp. 1082-1143, 2018, doi: 
10.1161/CIR.0000000000000625.
[5] R. Ferrari et al., “Current practice in 
identifying and treating cardiovascular 
risk, with a focus on residual risk 
associated with atherogenic 
dyslipidaemia,” Eur. Hear. Journal, 
Suppl., vol. 18, pp. C2–C12, 2016, doi: 
10.1093/eurheartj/suw009.
[6] J.-C. Fruchart et al., “Residual 
macrovascular risk in 2013: what have 
we learned? CARDIO VASCULAR 
DIABETOLOGY,” 2014. doi: 
10.1186/1475-2840-13-26.
[7] P. M. Ridker, “Clinician’s Guide to 
Reducing Inflammation to Reduce 
Atherothrombotic Risk: JACC Review 
Topic of the Week,” J. Am. Coll. 
Cardiol., vol. 72, no. 25, pp. 3320-3331, 
2018, doi: 10.1016/j.jacc.2018.06.082.
[8] A. Hernández-Mijares et al., 
“Residual cardiovascular risk of  
lipid origin. Components and 
pathophysiological aspects,” Clin. e 
Investig. en Arterioscler., vol. 31, no. 2, 
pp. 75-88, 2019, doi: 10.1016/j.
arteri.2018.06.007.
[9] F. Mach et al., “2019 ESC/EAS 
Guidelines for the management of 
dyslipidaemias: Lipid modification to 
reduce cardiovascular risk,” Eur. 
Heart J., vol. 41, no. 1, pp. 111-188, 
2020, doi: 10.1093/eurheartj/ehz455.
[10] Ž. Reiner, “Managing the residual 
cardiovascular disease risk associated 
with HDL-cholesterol and triglycerides 
in statin-treated patients: A clinical 
update,” Nutr. Metab. Cardiovasc. Dis., 
vol. 23, no. 9, pp. 799-807, 2013, doi: 
10.1016/j.numecd.2013.05.002.
[11] S. M. Grundy et al., “2018 AHA/
ACC/AACVPR/AAPA/ABC/ACPM/
ADA/AGS/APhA/ASPC/NLA/PCNA 
Guideline on the Management of Blood 
Cholesterol: A Report of the American 
College of Cardiology/American Heart 
Association Task Force on Clinical 
Practice Guidelines,” J. Am. Coll. 
Cardiol., vol. 73, no. 24, pp. e285–e350, 
2019, doi: 10.1016/j.jacc.2018.11.003.
[12] J. L. Goldstein and M. S. Brown, “A 
century of cholesterol and coronaries: 
From plaques to genes to statins,” Cell, 
vol. 161, no. 1, pp. 161-172, 2015, doi: 
10.1016/j.cell.2015.01.036.
[13] B. A. Ference et al., “Low-density 
lipoproteins cause atherosclerotic 
cardiovascular disease. 1. Evidence from 
genetic, epidemiologic, and clinical 
studies. A consensus statement from the 
European Atherosclerosis Society 
Consensus Panel,” Eur. Heart J., vol. 38, 
pp. 2459-2472, 2017, doi: 10.1093/
eurheartj/ehx144.
[14] C. Baigent et al., “Efficacy and 
safety of more intensive lowering of 
Cardiovascular Risk Factors
12
LDL cholesterol: A meta-analysis of data 
from 170 000 participants in 26 
randomised trials,” Lancet, vol. 376, no. 
9753, pp. 1670-1681, 2010, doi: 10.1016/
S0140-6736(10)61350-5.
[15] U. K. Sampson, S. Fazio, and M. F. 
Linton, “Residual Cardiovascular Risk 
Despite Optimal LDL-Cholesterol 
Reduction with Statins: The Evidence, 
Etiology, and Therapeutic Challenges,” 
Curr Atheroscler Rep, vol. 14, no. 1, pp. 
1-10, 2012, doi: 10.1007/s11883-011- 
0219-7.
[16] C. P. Cannon et al., “Intensive versus 
Moderate Lipid Lowering with Statins 
after Acute Coronary Syndromes,” N. 
Engl. J. Med., vol. 350, no. 15, pp. 
1495-1504, Apr. 2004, doi: 10.1056/
nejmoa040583.
[17] S. Sitia et al., “From endothelial 
dysfunction to atherosclerosis,” 
Autoimmun. Rev., vol. 9, no. 12, pp. 
830-834, 2010, doi: 10.1016/j.
autrev.2010.07.016.
[18] M. Gliozzi et al., “Molecular 
Sciences Modulation of Nitric Oxide 
Synthases by Oxidized LDLs: Role in 
Vascular Inflammation and 
Atherosclerosis Development,” 2019, 
doi: 10.3390/ijms20133294.
[19] J. Borén and K. J. Williams, “The 
central role of arterial retention of 
cholesterolrich apolipoprotein-B-
containing lipoproteins in the 
pathogenesis of atherosclerosis: A 
triumph of simplicity,” Curr. Opin. 
Lipidol., vol. 27, no. 5, pp. 473-483, 
2016, doi: 10.1097/MOL.0000000 
000000330.
[20] I. Tabas, K. J. Williams, and J. 
Borén, “Subendothelial lipoprotein 
retention as the initiating process in 
atherosclerosis: Update and therapeutic 
implications,” Circulation, vol. 116, no. 
16, pp. 1832-1844, 2007, doi: 10.1161/
CIRCULATIONAHA.106.676890.
[21] W. Liu, Y. Yin, Z. Zhou, M. He, and 
Y. Dai, “OxLDL-induced IL-1beta 
secretion promoting foam cells 
formation was mainly via CD36 
mediated ROS production leading to 
NLRP3 inflammasome activation,” 
Inflamm. Res., vol. 63, no. 1, pp. 33-43, 
2014, doi: 10.1007/s00011-013-0667-3.
[22] E. Mammen, “Fibrinogen 
Abnormalities,” Semin. Thromb. 
Hemost., vol. 9, no. 01, pp. 1-9, 1983, 
doi: 10.1055/s-2007-1004999.
[23] K. J. Moore, F. J. Sheedy, and E. A. 
Fisher, “Macrophages in atherosclerosis: 
A dynamic balance,” Nat. Rev. 
Immunol., vol. 13, no. 10, pp. 709-721, 
2013, doi: 10.1038/nri3520.
[24] A. Hultgårdh-Nilsson and M. 
Durbeej, “Role of the extracellular 
matrix and its receptors in smooth 
muscle cell function: Implications in 
vascular development and disease,” 
Curr. Opin. Lipidol., vol. 18, no. 5, pp. 
540-545, 2007, doi: 10.1097/
MOL.0b013e3282ef77e9.
[25] Y. Kiyan, S. Tkachuk, D. Hilfiker-
Kleiner, H. Haller, B. Fuhrman, and I. 
Dumler, “OxLDL induces inflammatory 
responses in vascular smooth muscle 
cells via urokinase receptor association 
with CD36 and TLR4,” J. Mol. Cell. 
Cardiol., vol. 66, pp. 72-82, 2014, doi: 
10.1016/j.yjmcc.2013.11.005.
[26] S. Vainio and E. Ikonen, 
“Macrophage cholesterol transport: a 
critical player in foam cell formation,” 
2009, doi: 10.1080/07853890310008198.
[27] M. M. Birck et al., “Endothelial cell 
death and intimal foam cell 
accumulation in the coronary artery of 
infected hypercholesterolemic 
minipigs,” J. Cardiovasc. Transl. Res., 
vol. 6, no. 4, pp. 579-587, 2013, doi: 
10.1007/s12265-013-9463-2.
[28] M. Budoff, T. T. and H. W. G. of the 
E. S. Project, and and B. I. National 
Heart, Lung, “Triglycerides and 
Triglyceride-Rich Lipoproteins in the 
13
Residual Cardiovascular Risk Factors in Dyslipidemia
DOI: http://dx.doi.org/10.5772/intechopen.100046
Causal Pathway of Cardiovascular 
Disease,” Am. J. Cardiol., no. Cv, 2016, 
doi: 10.1016/j.amjcard.2016.04.004.
[29] P. Libby, “Triglycerides on the rise: 
Should we swap seats on the seesaw?,” 
Eur. Heart J., vol. 36, no. 13, pp. 774-776, 
2015, doi: 10.1093/eurheartj/ 
ehu500.
[30] S. A. Khetarpal and D. J. Rader, 
“Triglyceride-rich lipoproteins and 
coronary artery disease risk: New 
insights from human genetics,” 
Arterioscler. Thromb. Vasc. Biol., vol. 
35, no. 2, pp. e3–e9, 2015, doi: 10.1161/
ATVBAHA.114.305172.
[31] H. Wang and R. H. Eckel, 
“Lipoprotein lipase: From gene to 
obesity,” Am. J. Physiol. Endocrinol. 
Metab., vol. 297, no. 2, 2009, doi: 
10.1152/ajpendo.90920.2008.
[32] “National Lipid Association 
recommendations for patient-centered 
management of dyslipidemia: Part 1 








921 (accessed Jun. 30, 2021).
[33] “24.Lipoprotein Lipase Mutations, 
Plasma Lipids and Lipoproteins, and 
Risk of Ischemic Heart Disease _ 
Enhanced Reader.pdf.”
[34] C. J et al., “Loss-of-Function 
Mutations in APOC3, Triglycerides, and 
Coronary Disease,” N. Engl. J. Med., vol. 
371, no. 1, pp. 22-31, 2014, doi: 10.1056/
nejmoa1307095.
[35] M. Kaltoft, A. Langsted, and B. G. 
Nordestgaard, “Triglycerides and 
remnant cholesterol associated with risk 
of aortic valve stenosis: Mendelian 
randomization in the Copenhagen 
General Population Study,” Eur. Heart J., 
vol. 41, no. 24, pp. 2288-2299, 2020, doi: 
10.1093/eurheartj/ehaa172.
[36] Allison A Brown and Frank B Hu, 
“Dietary modulation of endothelial 
function: implications for 
cardiovascular disease,” 2001. [Online]. 
Available: https://academic.oup.com/
ajcn/article/73/4/673/4737337.
[37] F. B. Hu et al., “Fish and Omega-3 
Fatty Acid Intake and Risk of Coronary 
Heart Disease in Women,” 2002. 
[Online]. Available: https://
jamanetwork.com/.
[38] F. B. Hu, E. Cho, K. M. Rexrode, C. 
M. Albert, and J. E. Manson, “Fish and 
Long-Chain-3 Fatty Acid Intake and 
Risk of Coronary Heart Disease and 
Total Mortality in Diabetic Women,” 
Circulation, vol. 107, pp. 1852-1857, 
2003, doi: 10.1161/01.CIR.0000062 
644.42133.5F.
[39] “n–3 Fatty Acids and Cardiovascular 
Outcomes in Patients with 
Dysglycemia,” N. Engl. J. Med., vol. 367, 
no. 4, pp. 309-318, 2012, doi: 10.1056/
nejmoa1203859.
[40] S. J. Nicholls et al., “Effect of 
High-Dose Omega-3 Fatty Acids vs Corn 
Oil on Major Adverse Cardiovascular 
Events in Patients at High 
Cardiovascular Risk: The STRENGTH 
Randomized Clinical Trial,” JAMA - J. 
Am. Med. Assoc., vol. 324, no. 22, pp. 
2268-2280, 2020, doi: 10.1001/
jama.2020.22258.
[41] D. L. Bhatt et al., “Cardiovascular 
Risk Reduction with Icosapent Ethyl for 
Hypertriglyceridemia,” N. Engl. J. Med., 
vol. 380, no. 1, pp. 11-22, 2019, doi: 
10.1056/nejmoa1812792.
[42] M. J. Budoff et al., “Effect of 
icosapent ethyl on progression of 
coronary atherosclerosis in patients with 
elevated triglycerides on statin therapy: 




[43] J. Stamler, “Clofibrate and Niacin in 
Coronary Heart Disease,” JAMA J. Am. 
Med. Assoc., vol. 231, no. 4, pp. 360-
381, 1975, doi: 10.1001/jama.1975. 
03240160024021.
[44] H. B. Rubinsv et al., “Gemfibrozil 
for the Secondary Prevention of 
Coronary Heart Disease in Men with 
Low Levels of High-Density Lipoprotein 
Cholesterol,” J. Cardiopulm. Rehabil., 
vol. 20, no. 1, p. 66, 2000, doi: 10.1097/ 
00008483-200001000-00015.
[45] B. Marshall et al., “Effects of 
Combination Lipid Therapy in Type 2 
Diabetes Mellitus,” pp. 1563-1574,  
2010.
[46] M. Jun et al., “Effects of fibrates on 
cardiovascular outcomes: a systematic 
review and meta-analysis,” Lancet, vol. 
375, no. 9729, pp. 1875-1884, 2010, doi: 
10.1016/S0140-6736(10)60656-3.
[47] V. J. Alexander et al., “N-acetyl 
galactosamine-conjugated antisense 
drug to APOC3 mRNA, triglycerides 
and atherogenic lipoprotein levels,” Eur. 
Heart J., vol. 40, no. 33, pp. 2785-2796, 
2019, doi: 10.1093/eurheartj/ehz209.
[48] P. H. Joshi et al., “Remnant 
Lipoprotein Cholesterol and Incident 
Coronary Heart Disease: The Jackson 
Heart and Framingham Offspring 
Cohort Studies,” J. Am. Heart Assoc., 
vol. 5, no. 5, 2016, doi: 10.1161/
JAHA.115.002765.
[49] S. Bandeali and J. Farmer, “High-
density lipoprotein and atherosclerosis: 
The role of antioxidant activity,” Curr. 
Atheroscler. Rep., vol. 14, no. 2, pp. 
101-107, 2012, doi: 10.1007/
s11883-012-0235-2.
[50] D. J. Gordon et al., “High-density 
lipoprotein cholesterol and 
cardiovascular disease. Four prospective 
American studies,” Circulation, vol. 79, 
no. 1, pp. 8-15, 1989, doi: 10.1161/01.
CIR.79.1.8.
[51] G. L. Moneta, “Major Lipids, 
Apolipoproteins, and Risk of Vascular 
Disease,” Yearb. Vasc. Surg., vol. 2010, 
no. 18, pp. 42-44, 2010, doi: 10.1016/
s0749-4041(10)79320-9.
[52] B. F. Voight et al., “Plasma HDL 
cholesterol and risk of myocardial 
infarction: A mendelian randomisation 
study,” Lancet, vol. 380, no. 9841, pp. 
572-580, 2012, doi: 10.1016/S0140-6736 
(12)60312-2.
[53] R. Frikke-Schmidt et al., 
“Association of Loss-of-Function 
Mutations in the ABCA1 Gene With 
High-Density,” JAMA, vol. 299, no. 21, 
pp. 2524-2532, 2008.
[54] D. Rhainds and L. Brissette, “The 
role of scavenger receptor class B type I 
(SR-BI) in lipid trafficking: Defining the 
rules for lipid traders,” Int. J. Biochem. 
Cell Biol., vol. 36, no. 1, pp. 39-77, 2004, 
doi: 10.1016/S1357-2725(03)00173-0.
[55] P. Zanoni et al., “Rare variant in 
scavenger receptor BI raises HDL 
cholesterol and increases risk of 
coronary heart disease,” 2016. [Online]. 
Available: http://science.sciencemag. 
org/.
[56] B. Agerholm-Larsen, B. G. 
Nordestgaard, R. Steffensen, G. Jensen, 
and A. Tybjærg-Hansen, “Elevated HDL 
cholesterol is a risk factor for ischemic 
heart disease in white women when 
caused by a common mutation in the 
cholesteryl ester transfer protein gene,” 
Circulation, vol. 101, no. 16, pp. 1907-
1912, 2000, doi: 10.1161/01.CIR.101. 
16.1907.
[57] A. Thompson et al., “Association of 
cholesteryl ester transfer protein 
genotypes with CETP mass and activity, 
lipid levels, and coronary risk,” JAMA -  
J. Am. Med. Assoc., vol. 299, no. 23, pp. 
2777-2788, 2008, doi: 10.1001/
jama.299.23.2777.
[58] Ž. Reiner et al., “ESC/EAS 
Guidelines for the management of 
15
Residual Cardiovascular Risk Factors in Dyslipidemia
DOI: http://dx.doi.org/10.5772/intechopen.100046
dyslipidaemias,” Eur. Heart J., vol. 32, 
no. 14, pp. 1769-1818, 2011, doi: 10.1093/
eurheartj/ehr158.
[59] J. Perk et al., “European Guidelines 
on cardiovascular diseaseprevention in 
clinical practice (version 2012): The 
Fifth Joint Task Force of the European 
Society of Cardiologyand Other 
Societies on Cardiovascular Disease 
Prevention in ClinicalPractice 
(constituted by representatives of nine 
societiesand by invited experts),” vol. 1, 
no. 5, 2012, doi: 10.1093/eurheartj/ 
ehs092.
[60] M. B. Mortensen, S. Afzal, B. G. 
Nordestgaard, and E. Falk, “The 
high-density lipoprotein-adjusted 
SCORE model worsens SCORE-based 
risk classification in a contemporary 
population of 30 824 Europeans: The 
Copenhagen General Population Study,” 
Eur. Heart J., vol. 36, no. 36, pp. 2446-
2453, 2015, doi: 10.1093/eurheartj/ 
ehv251.
[61] H. et. al Hampel, “Niacin in Patients 
with Low HDL Cholesterol Levels 
Receiving Intensive Statin Therapy,” N. 
Engl. J. Med., pp. 687-696, 2011.
[62] M. J. Landray et al., “Effects of 
Extended-Release Niacin with 
Laropiprant in High-Risk Patients,” N. 
Engl. J. Med., vol. 371, no. 3, pp. 203-
212, 2014, doi: 10.1056/nejmoa1300955.
[63] “Effects of Anacetrapib in Patients 
with Atherosclerotic Vascular Disease,” 
N. Engl. J. Med., vol. 377, no. 13, pp. 
1217-1227, 2017, doi: 10.1056/
nejmoa1706444.
[64] P. J. Barter, M. Caulfield, and M. 
Eriksson, “Effects of torcetrapib in 
patients at high risk for coronary 
events,” J. Vasc. Surg., vol. 47, no. 4, p. 
893, 2008, doi: 10.1016/j.jvs.2008.02.014.
[65] G. G. Schwartz et al., “Effects of 
Dalcetrapib in Patients with a Recent 
Acute Coronary Syndrome A bs t r ac t,” 
N Engl J Med, vol. 367, pp. 2089-2099, 
2012, doi: 10.1056/NEJMoa1206797.
[66] A. Lincoff, S. Nicholls, J. Riesmeyer, 
P. Barter, H. Brewer, and K. Fox, 
“Evacetrapib and Cardiovascular 
Outcomes in High-Risk Vascular 
Disease,” 2017. doi: 10.1016/j.
jvs.2017.08.007.
[67] C. M. Madsen and B. G. 
Nordestgaard, “Is it time for new 
thinking about high-density 
lipoprotein?,” Arterioscler. Thromb. 
Vasc. Biol., vol. 38, no. 3, pp. 484-486, 
2018, doi: 10.1161/ATVBAHA.118. 
310727.
[68] C. M. Madsen, A. Varbo, and B. G. 
Nordestgaard, “Extreme high high-
density lipoprotein cholesterol is 
paradoxically associated with high 
mortality inmen and women: Two 
prospective cohort studies,” Eur. 
Heart J., vol. 38, no. 32, pp. 2478-2486, 
2017, doi: 10.1093/eurheartj/ehx163.
[69] M. Hamer, G. O’Donovan, and E. 
Stamatakis, “High-density lipoprotein 
cholesterol and mortality too much of a 
good thing?,” Arterioscler. Thromb. 
Vasc. Biol., vol. 38, no. 3, pp. 669-672, 
2018, doi: 10.1161/ATVBAHA.117.310587.
[70] R. C. Maranhão, P. O. Carvalho, C. 
Cassaro Strunz, and F. Pileggi, 
“Lipoprotein (a): Structure, 
Pathophysiology and Clinical 
Implications,” 2013, doi: 10.5935/
abc.20140101.
[71] E. Steyrer et al., “The role of 
lecithin: Cholesterol acyltransferase for 
lipoprotein (a) assembly. Structural 
integrity of low density lipoproteins is a 
prerequisite for Lp(a) formation in 
human plasma,” J. Clin. Invest., vol. 94, 
no. 6, pp. 2330-2340, 1994, doi: 10.1172/
JCI117598.
[72] M. B. Boffa, S. M. Marcovina, and 
M. L. Koschinsky, “Lipoprotein(a) as a 
risk factor for atherosclerosis and 
Cardiovascular Risk Factors
16
thrombosis: Mechanistic insights from 
animal models,” Clin. Biochem., vol. 37, 
no. 5, pp. 333-343, 2004, doi: 10.1016/j.
clinbiochem.2003.12.007.
[73] M. Poon, X. Zhang, K. Dunsky, M. 
B. Taubman, and P. C. Harpel, 
“Apolipoprotein(a) is a human vascular 
endothelial cell agonist: Studies on the 
induction in endothelial cells of 
monocyte chemotactic factor activity,” 
Clin. Genet., vol. 52, no. 5, pp. 308-313, 
1997, doi: 10.1111/j.1399-0004.1997.
tb04348.x.
[74] U. Kassner, T. Schlabs, A. Rosada, 
and E. Steinhagen-Thiessen, 
“Lipoprotein(a) - An independent 
causal risk factor for cardiovascular 
disease and current therapeutic 
options,” Atheroscler. Suppl., vol. 18, pp. 
263-267, 2015, doi: 10.1016/j.
atherosclerosissup.2015.02.039.
[75] S. Erqou et al., “Lipoprotein(a) 
Concentration and the Risk of Coronary 
Heart Disease, Stroke, and Nonvascular 
Mortality,” Jama-Journal Am. Med. 
Assoc., vol. 302, no. 4, pp. 412-423, 
2009, [Online]. Available: http://jama.
jamanetwork.com/.
[76] M. Mcqueen et al., “Lipoprotein ( a ) 
Levels and the Risk of Myocardial 
Infarction Among Seven Ethnic 
Groups,” vol. 8, no. 905.
[77] A. V. Khera et al., “Lipoprotein(a) 
concentrations, rosuvastatin therapy, 
and residual vascular risk: An analysis 
from the JUPITER trial (justification for 
the use of statins in prevention: An 
intervention trial evaluating 
rosuvastatin),” Circulation, vol. 129, no. 
6, pp. 635-642, 2014, doi: 10.1161/
CIRCULATIONAHA.113.004406.
[78] M. L. O’Donoghue et al., 
“Lipoprotein(a), PCSK9 inhibition, and 
cardiovascular risk insights from the 
FOURIER trial,” Circulation, vol. 139, 
no. 12, pp. 1483-1492, 2019, doi: 10.1161/
CIRCULATIONAHA.118. 
037184.
[79] W. Q. Wei et al., “LPA variants are 
associated with residual cardiovascular 
risk in patients receiving statins,” 
Circulation, vol. 138, no. 17, pp.  
1839-1849, 2018, doi: 10.1161/
CIRCULATIONAHA.117.031356.
[80] S. Burgess et al., “Association of LPA 
variants with risk of coronary disease 
and the implications for lipoprotein(a)-
lowering therapies: A mendelian 
randomization analysis,” JAMA 
Cardiol., vol. 3, no. 7, pp. 619-627, 2018, 
doi: 10.1001/jamacardio.2018.1470.
[81] A. Langsted, B. G. Nordestgaard, M. 
Benn, A. Tybjaerg-Hansen, P. R. 
Kamstrup, and G. Hospital, “PCSK9 
R46L Loss-of-Function Mutation 
Reduces Lipoprotein(a), LDL 
Cholesterol, and Risk of Aortic Valve 
Stenosis and The Copenhagen General 
Population Study (A,” J Clin Endocrinol 
Metab, vol. 101, pp. 3281-3287, 2016, 
doi: 10.1210/jc.2016-1206.
[82] M. Szarek et al., “Lipoprotein(a) 
lowering by alirocumabreduces the  
total burden of cardiovascularevents 
independent of low-densitylipo 
protein cholesterol lowering: 
ODYSSEYOUTCOMES trial,” Eur. 
Heart J., vol. 41, pp. 4245-4255, 2020, 
doi: 10.1093/eurheartj/ehaa842.
[83] A. F. Schmidt et al., “PCSK9 
monoclonal antibodies for the primary 
and secondary prevention of 
cardiovascular disease,” Cochrane 
Database Syst. Rev., vol. 2020, no. 12, 
2020, doi: 10.1002/14651858.CD011748. 
pub3.
[84] S. Tsimikas et al., “Lipoprotein(a) 
Reduction in Persons with 
Cardiovascular Disease,” N. Engl. J. 
Med., vol. 382, no. 3, pp. 244-255, 2020, 
doi: 10.1056/nejmoa1905239.
[85] N. J. Viney et al., “Antisense 
oligonucleotides targeting 
apolipoprotein(a) in people with raised 
lipoprotein(a): two randomised, 
17
Residual Cardiovascular Risk Factors in Dyslipidemia
DOI: http://dx.doi.org/10.5772/intechopen.100046
double-blind, placebo-controlled, 
dose-ranging trials,” Lancet, vol. 388, 
no. 10057, pp. 2239-2253, 2016, doi: 
10.1016/S0140-6736(16)31009-1.
[86] C. P. Cannon et al., “Ezetimibe 
Added to Statin Therapy after Acute 
Coronary Syndromes,” N. Engl. J. Med., 
vol. 372, no. 25, pp. 2387-2397, 2015, doi: 
10.1056/nejmoa1410489.
[87] M. S. Sabatine et al., “Evolocumab 
and Clinical Outcomes in Patients with 
Cardiovascular Disease,” N. Engl. J. 
Med., vol. 376, no. 18, pp. 1713-1722, 
2017, doi: 10.1056/nejmoa1615664.
[88] G. A. Nichols, S. Philip, K. 
Reynolds, C. B. Granowitz, and S. Fazio, 
“Increased Cardiovascular Risk in 
Hypertriglyceridemic Patients With 
Statin-Controlled LDL Cholesterol,” J 
Clin Endocrinol Metab, vol. 103, pp. 
3019-3027, 2018, doi: 10.1210/
jc.2018-00470.
[89] W. Koenig, “High-sensitivity 
C-reactive protein and atherosclerotic 
disease: From improved risk prediction 
to risk-guided therapy,” Int. J. Cardiol., 
vol. 168, no. 6, pp. 5126-5134, 2013, doi: 
10.1016/j.ijcard.2013.07.113.
[90] E. A. Bohula et al., “Achievement of 
dual low-density lipoprotein cholesterol 
and high-sensitivity c-reactive protein 
targets more frequent with the addition 
of ezetimibe to simvastatin and 
associated with better outcomes in 
IMPROVE-IT,” Circulation, vol. 132, no. 
13, pp. 1224-1233, 2015, doi: 10.1161/
CIRCULATIONAHA.115.018381.
[91] P. M. Ridker et al., 
“Antiinflammatory Therapy with 
Canakinumab for Atherosclerotic 
Disease,” N. Engl. J. Med., vol. 377, no. 
12, pp. 1119-1131, 2017, doi: 10.1056/
nejmoa1707914.
[92] R. Collins et al., “Aspirin in the 
primary and secondary prevention of 
vascular disease: collaborative 
meta-analysis of individual participant 
data from randomised trials,” Lancet, 
vol. 373, no. 9678, pp. 1849-1860, 2009, 
doi: 10.1016/S0140-6736(09)60503-1.
[93] G. Gallone et al., “Medical Therapy 
for Long-Term Prevention of 
Atherothrombosis Following an Acute 
Coronary Syndrome: JACC State-of-the-
Art Review,” J. Am. Coll. Cardiol., vol. 
72, no. 23, pp. 2886-2903, 2018, doi: 
10.1016/j.jacc.2018.09.052.
[94] J. W. Eikelboom et al., “Rivaroxaban 
with or without Aspirin in Stable 
Cardiovascular Disease,” N. Engl. J. 
Med., vol. 377, no. 14, pp. 1319-1330, 
2017, doi: 10.1056/nejmoa1709118.
[95] S. S. Anand et al., “Rivaroxaban 
with or without aspirin in patients with 
stable peripheral or carotid artery 
disease: an international, randomised, 
double-blind, placebo-controlled trial,” 
Lancet, vol. 391, no. 10117, pp. 219-229, 
2018, doi: 10.1016/S0140-6736(17) 
32409-1.
[96] R. C. Hoogeveen and C. M. 
Ballantyne, “Residual Cardiovascular 
Risk at Low LDL: Remnants, 
Lipoprotein(a), and Inflammation,” 
Clin. Chem., vol. 67, no. 1, pp. 143-153, 
2021, doi: 10.1093/clinchem/hvaa252.
[97] M. R. Langlois et al., “Quantifying 
atherogenic lipoproteins for lipid-
lowering strategies: Consensus-based 
recommendations from EAS and 
EFLM,” Clin. Chem. Lab. Med., vol. 58, 
no. 4, pp. 496-517, 2020, doi: 10.1515/
cclm-2019-1253.
[98] F. Schiele et al., “The FAST-MI 
2005-2010-2015 registries in the light of 
the COMPASS trial: The COMPASS 
criteria applied to a post-MI 
population,” Int. J. Cardiol., vol. 278, no. 
xxxx, pp. 7-13, 2019, doi: 10.1016/j.
ijcard.2018.11.138.
[99] D. D. McManus, J. Gore, J. 
Yarzebski, F. Spencer, D. Lessard, and 
Cardiovascular Risk Factors
18
R. J. Goldberg, “Recent trends in the 
incidence, treatment, and outcomes of 
patients with STEMI and NSTEMI,” 
Am. J. Med., vol. 124, no. 1, pp. 40-47, 
2011, doi: 10.1016/j.amjmed.2010. 
07.023.
[100] M. Hall et al., “Association of 
clinical factors and therapeutic 
strategies with improvements in 
survival following Non-ST-elevation 
myocardial infarction, 2003-2013,” 
JAMA - J. Am. Med. Assoc., vol. 316, no. 
10, pp. 1073-1082, 2016, doi: 10.1001/
jama.2016.10766.
[101] P. M. Ridker et al., “Relationship of 
C-reactive protein reduction to 
cardiovascular event reduction 
following treatment with canakinumab: 
a secondary analysis from the CANTOS 
randomised controlled trial,” Lancet, 
vol. 391, no. 10118, pp. 319-328, 2018, 
doi: 10.1016/S0140-6736(17)32814-3.
[102] P. Mani et al., “Association of Initial 
and Serial C-Reactive Protein Levels 
With Adverse Cardiovascular Events 
and Death After Acute Coronary 
Syndrome A Secondary Analysis of the 
VISTA-16 Trial,” 2019, doi: 10.1001/
jamacardio.2019.0179.
[103] J. L. Mega et al., “Rivaroxaban in 
Patients with a Recent Acute Coronary 
Syndrome,” n engl j med, vol. 366, 2012, 
doi: 10.1056/NEJMoa1112277.
[104] G. A. Nichols, S. Philip PharmD, K. 
Reynolds, C. B. Granowitz, S. Fazio, and 
C. A. Gregory Nichols, “Increased 
residual cardiovascular risk in patients 
with diabetes and high versus normal 
triglycerides despite statin-controlled 
LDL cholesterol,” 2018, doi: 10.1111/
dom.13537.
[105] M. Szarek et al., “Alirocumab 
Reduces Total Nonfatal Cardiovascular 
and Fatal Events: The ODYSSEY 
OUTCOMES Trial,” J. Am. Coll. 
Cardiol., vol. 73, no. 4, pp. 387-396, 
2019, doi: 10.1016/j.jacc.2018.10.039.
[106] H. Ghandehari, S. Kamal-Bahl, and 
N. D. Wong, “Prevalence and extent of 
dyslipidemia and recommended lipid 
levels in US adults with and without 
cardiovascular comorbidities: The 
National Health and Nutrition 
Examination Survey 2003-2004,” Am. 
Heart J., vol. 156, no. 1, pp. 112-119, 
2008, doi: 10.1016/j.ahj.2008.03.005.
[107] S. Dash and L. A. Leiter, “Residual 
cardiovascular risk among people with 
diabetes,” Diabetes, Obes. Metab., vol. 
21, no. S1, pp. 28-38, Apr. 2019, doi: 
10.1111/dom.13646.
